Bempedoic acid gets activated in liver to an active metaboliteActivated drug inhibits the enzyme ATP Citrate lyase (ACLY)Oral dose, 180mg once dailyElimination half-life is 15–24 hoursInitial trials showed LDL-C lowering efficacy of upto 27% as monotherapyAdded LDL lowering of upto 48% with Bempedoic acid and ezetimibe combinationLower incidence of myopathy compared with statin. The gene discussed is ACLY; the disease is myopathy.